Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Jason Montgomery

Physician Assistant, Medical Muncie, IN Physician Assistant

NPI 1104835594 CMS profile 10650634

3750 N Briarwood Ln, Muncie, IN 47304

Open in the dashboard

General payments

$5,592

45 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jason Montgomery of Muncie, IN is reported in the CMS Open Payments database as having received $5,592 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $200 1
2023 General $2,936 22
2022 General $1,314 15
2021 General $1,141 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Montgomery
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jason Montgomery were reported at $0. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jason Montgomery Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,141 $156 $41–$563 $132
2022 $1,314 $185 $55–$649 $149
2023 $2,936 $199 $58–$717 $160
2024 $200 $206 $62–$740 $164
2025 $0 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Spinal Simplicity, LLC $4,086 28 payments
  2. MML US, Inc. $962 3 payments
  3. MicroVention, Inc. $200 1 payment
  4. Boston Scientific Corporation $103 4 payments
  5. Nevro Corp. $100 1 payment
  6. Relievant Medsystems, Inc. $29 1 payment
  7. Biohaven Pharmaceutical Holding Company Ltd. $25 2 payments
  8. CutisPharma, Inc. $23 1 payment
  9. Abbott Laboratories $19 1 payment
  10. AbbVie, Inc. $17 1 payment
  11. Other $28 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Travel and Lodging $3,681 14 payments
  2. Food and Beverage $1,910 31 payments
Products named General payments · program years 2021–2024
  1. HA MINUTEMAN G3-R $4,086 28 payments
  2. ReActiv8 $962 3 payments
  3. WEB ANEURYSM EMBOLIZATION SYSTEM $200 1 payment
  4. Omnia $100 1 payment
  5. WaveWriter Alpha Prime 16 $42 2 payments
  6. GENERAL PAIN MANAGEMENT $38 1 payment
  7. Intracept Pain $29 1 payment
  8. Intracept Pain $29 1 payment
  9. NURTEC ODT $25 2 payments
  10. General - Pain Management $23 1 payment
  11. Other $86 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

795

Median for Physician Assistant: 241

Drug cost

$19,119

Median for Physician Assistant: $4,110

Branded share of claims

66.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 188 $5,604
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 266 $5,468
Morphine Sulfate Er Morphine Sulfate Brand 77 $2,055
Pregabalin Generic 42 $1,815
Fentanyl Generic 14 $1,336
Gabapentin Generic 80 $1,232
Oxycodone Hcl Generic 34 $578
Tizanidine Hcl Generic 48 $504
Hydromorphone Hcl Generic 14 $222
Methadone Hcl Generic 14 $210

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$28,477

Medicare's payments for the services billed

Medicare patients

109

Average age 71

Services billed

346

77 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 47%
Diabetes 38%
Heart failure 31%
Chronic kidney disease 31%
COPD 29%
Ischemic heart disease 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record